PT3801546T - Composto de indol para o tratamento de cistite intersticial - Google Patents

Composto de indol para o tratamento de cistite intersticial

Info

Publication number
PT3801546T
PT3801546T PT197338858T PT19733885T PT3801546T PT 3801546 T PT3801546 T PT 3801546T PT 197338858 T PT197338858 T PT 197338858T PT 19733885 T PT19733885 T PT 19733885T PT 3801546 T PT3801546 T PT 3801546T
Authority
PT
Portugal
Prior art keywords
treating pain
interstitial cystitis
indole compound
indole
compound
Prior art date
Application number
PT197338858T
Other languages
English (en)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PT3801546T publication Critical patent/PT3801546T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT197338858T 2018-05-25 2019-05-24 Composto de indol para o tratamento de cistite intersticial PT3801546T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018100671 2018-05-25
JP2018246392 2018-12-28
US201962835675P 2019-04-18 2019-04-18

Publications (1)

Publication Number Publication Date
PT3801546T true PT3801546T (pt) 2024-08-08

Family

ID=67070891

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197338858T PT3801546T (pt) 2018-05-25 2019-05-24 Composto de indol para o tratamento de cistite intersticial

Country Status (21)

Country Link
US (2) US11464782B2 (pt)
EP (2) EP3801546B1 (pt)
JP (4) JP6775699B2 (pt)
KR (1) KR102725563B1 (pt)
CN (1) CN112118843B (pt)
AU (1) AU2019274870B2 (pt)
BR (1) BR112020022377A2 (pt)
CA (1) CA3100675A1 (pt)
DK (1) DK3801546T3 (pt)
ES (1) ES2983998T3 (pt)
FI (1) FI3801546T3 (pt)
HR (1) HRP20241045T1 (pt)
HU (1) HUE067906T2 (pt)
LT (1) LT3801546T (pt)
MX (1) MX2020012644A (pt)
PL (1) PL3801546T3 (pt)
PT (1) PT3801546T (pt)
RS (1) RS65837B1 (pt)
SI (1) SI3801546T1 (pt)
SM (1) SMT202400314T1 (pt)
WO (1) WO2019225768A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
US12011448B2 (en) 2018-05-25 2024-06-18 Japan Tobacco Inc. Therapeutic or preventing agent for nephrotic syndrome including indole compound
EP4077316A1 (en) 2019-12-20 2022-10-26 Pfizer Inc. Benzimidazole derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
CN104628657A (zh) 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
JP6596417B2 (ja) * 2014-07-04 2019-10-23 日本たばこ産業株式会社 インドール化合物の製造方法
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
US12011448B2 (en) 2018-05-25 2024-06-18 Japan Tobacco Inc. Therapeutic or preventing agent for nephrotic syndrome including indole compound

Also Published As

Publication number Publication date
LT3801546T (lt) 2024-08-12
PL3801546T3 (pl) 2024-10-28
US20210205320A1 (en) 2021-07-08
KR102725563B1 (ko) 2024-11-05
CN112118843B (zh) 2023-09-29
SMT202400314T1 (it) 2024-09-16
ES2983998T3 (es) 2024-10-28
JP2020525413A (ja) 2020-08-27
WO2019225768A1 (en) 2019-11-28
EP3801546B1 (en) 2024-07-17
KR20210014656A (ko) 2021-02-09
EP4480484A1 (en) 2024-12-25
SI3801546T1 (sl) 2024-09-30
FI3801546T3 (fi) 2024-09-05
US20250152596A1 (en) 2025-05-15
BR112020022377A2 (pt) 2021-02-02
JP6775699B2 (ja) 2020-10-28
EP3801546A1 (en) 2021-04-14
CN112118843A (zh) 2020-12-22
AU2019274870B2 (en) 2024-08-08
HUE067906T2 (hu) 2024-11-28
AU2019274870A1 (en) 2020-12-17
US11464782B2 (en) 2022-10-11
JP2026048781A (ja) 2026-03-17
JP2021008496A (ja) 2021-01-28
HRP20241045T1 (hr) 2024-11-08
JP2024096817A (ja) 2024-07-17
RS65837B1 (sr) 2024-09-30
MX2020012644A (es) 2021-01-29
CA3100675A1 (en) 2019-11-28
DK3801546T3 (da) 2024-08-12

Similar Documents

Publication Publication Date Title
GB201804514D0 (en) Treatment of pyroptosis
IL286938A (en) Methods for treating neuropathic pain
SG11202104222TA (en) Method of treatment of biological surfaces
GB201706406D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
IL287210A (en) Preparations for the treatment of tumors
GB201815588D0 (en) Method of treatment
IL290983A (en) Treatment methods
PT3801546T (pt) Composto de indol para o tratamento de cistite intersticial
GB201804515D0 (en) Treatment of necroptosis
IL287250A (en) treatment method
SG11202105877YA (en) Method of treatment
GB201918853D0 (en) Methods of treatment
SG11202103999VA (en) Methods of treatment using anti-cd123 immunoconjugates
SG11202102240YA (en) Methods of treating psoriasis
IL277962A (en) Methods for treating neuropathic pain
IL268111A (en) Methods of treating pain
GB201820975D0 (en) Methods of cancer treatment
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
GB201806569D0 (en) Method of treatment
GB201804021D0 (en) Method of treatment
GB201900942D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment
HK40062182A (en) Method of treatment